It was with great pride that the CHS learned that the World Federation of Hemophilia (WFH) had granted the 2022 Hemophilia Organization Twins of the...
The CHS is deeply saddened to learn of the passing of Dr. Ronald George. We would like to offer our sincere condolences to his wife...
CLICK HERE to meet the 2023 James Kreppner Scholarship and Bursary recipients.
Montreal – May 23, 2023 – The Canadian Hemophilia Society has learned that Health Canada recently approved Alhemo (concizumab) for the treatment of people, ages...
Please CLICK HERE to access the 2022 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking HERE.
The Commission of Inquiry on the Blood System in Canada was a public investigation of the Canadian blood system, which had been contaminated with HIV...
Following the development of the Canadian Integrated and Comprehensive Care Standards for Inherited Bleeding Disorders (Second Edition) in 2020, the Canadian Inherited Bleeding Disorder Standards...
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE....
by James Bayford – Kelowna, British Columbia “Why?” Is a question I asked myself as I laced up my running shoes before a scheduled 20...
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
This past summer, the Canadian Hemophilia Society (CHS) conducted an on-line survey on attitudes to and knowledge about gene therapy. The results were presented and...
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...